ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment
Asian Journal of Andrology · 2023
DOI: 10.4103/aja202230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Andrology, 2023. Verfasst von Jeanny B Aragon-Ching. Beteiligte Einrichtung: GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA.
Zitieren
APA
Aragon-Ching, J. B. (2023). ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment. Asian Journal of Andrology. https://doi.org/10.4103/aja202230
Vancouver
Aragon-Ching JB. ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment. Asian Journal of Andrology. 2023. doi:10.4103/aja202230
BibTeX
@article{AragonChing2023,
author = {Aragon-Ching, Jeanny B},
title = {ARASENS: making sense out of first-line metastatic hormone-sensitive prostate cancer treatment},
journal = {Asian Journal of Andrology},
year = {2023},
doi = {10.4103/aja202230}
}
EUVIMED